Related Experiment Video
Updated: Sep 11, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Impact of Protocol Amendments, Personnel Experience and Social Determinants of Health on Study Protocol Adherence in
K N Cilley1, A O Kaliaev2, M A Malikova3
1Department of Surgery, Boston University, Chobanian and Avedisian School of Medicine, Boston Medical Center, 85 East Concord Street, 02118, Boston, MA, United States.
Introduction:
The amendments to the International Council for Harmonization (ICH) Good Clinical Practice (GCP) E8 guidelines were introduced to enhance clinical trial quality, patient safety, and efficiency through a more patient-centric, risk-based approach. This study investigates the impact of various study risk factors such as protocol amendments, informed consent changes, protocol complexity, and social determinants of health (SDOH) on protocol deviations and patient retention in clinical trials involving combination products.
Methods:
A retrospective analysis of 14 clinical trials with 202 enrolled subjects was conducted. Key risk indicators (KRIs) such as protocol amendments, amendments triggering informed consent changes, study staff experience, and clinical trial phase were evaluated for their association with protocol deviations. The analysis also explored the influence of social factors, including age, gender, race, insurance type, and travel distance on protocol adherence.
Results:
Study revealed that longer study participation was associated with an increased number of protocol deviations (p = 0.0003), while no significant associations were found between protocol deviations and demographic factors (p = 0.4039 for gender; p = 0.40650 for age), insurance type (p = 0.0640), or complexity scores (p = 0.7798). The findings highlight the importance of effective informed consent processes, study staff training, and risk management strategies to minimize protocol deviations and enhance data integrity in clinical trials.
Conclusion:
while larger numbers of participant were associated with more deviations, site preparedness and patient compliance can mitigate these risks, underscoring the need for robust quality management systems in clinical trials.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Factors Affecting Drug Response: Overview
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

